3 Schizophrenia Clinical Trials in Rogers, AR (2026)

Q: How do I join a clinical trial in Rogers?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Rogers research site will contact you.

Recruiting Schizophrenia Studies in Rogers

NCT05184335Recruiting

Safety and Efficacy of Brilaroxazine (RP5063) in Schizophrenia

This study is to evaluate the effect and safety of Brilaroxazine in patients with acute schizophrenia compared to the placebo short and long-term. Brilaroxazine will be given at fixed doses of 15 mg o...

Rogers, ARPHASE3690 participantsReviva Pharmaceuticals

View Study Details

NCT06894212Recruiting

A Trial of the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia

This is a Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Determine the the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants with Schizophrenia...

Rogers, ARPHASE3522 participantsOtsuka Pharmaceutical Development & Commercialization, Inc.

View Study Details

NCT06961968Recruiting

Randomized Withdrawal Study in Patients With Schizophrenia

The purpose of this research is to evaluate the efficacy of dosing iloperidone long-acting injection (LAI) compared to placebo in preventing the exacerbation of symptoms in patients with schizophrenia...

Rogers, ARPHASE3400 participantsVanda Pharmaceuticals

View Study Details

About Schizophrenia Clinical Trials in Rogers

Schizophrenia is a chronic brain disorder affecting approximately 2.8 million US adults, characterized by hallucinations, delusions, disorganized thinking, and cognitive difficulties. While current treatments rely primarily on first- and second-generation antipsychotics (risperidone, olanzapine, clozapine), many patients experience incomplete symptom relief or significant side effects. Clinical trials are testing novel mechanisms including muscarinic receptor agonists (like KarXT/xanomeline-trospium), trace amine-associated receptor 1 (TAAR1) agonists, glutamate modulators, and long-acting injectable formulations. Treatment-resistant schizophrenia remains a major focus area, with trials seeking patients who have not adequately responded to standard antipsychotic therapy.

There are currently 3 schizophrenia clinical trials recruiting participants in Rogers, AR. These studies are seeking a combined 1,612 participants. Research is being sponsored by Reviva Pharmaceuticals, Otsuka Pharmaceutical Development & Commercialization, Inc., Vanda Pharmaceuticals. Clinical trial participation is free and participants receive study-related medical care at no cost.

Schizophrenia Clinical Trials in Rogers — FAQ

Are there schizophrenia clinical trials in Rogers?

Yes, there are 3 schizophrenia clinical trials currently recruiting in Rogers, AR. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Rogers?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Rogers research site will contact you about next steps.

Are clinical trials in Rogers free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Rogers studies also compensate for your time and travel.

What schizophrenia treatments are being tested?

The 3 active trials in Rogers are testing new therapies including novel drugs, biologics, and treatment approaches for schizophrenia.

Data updated July 22, 2026 from ClinicalTrials.gov